Pfizer Inc. (NYSE:PFE) Shares Bought by Independent Advisor Alliance

Independent Advisor Alliance raised its holdings in Pfizer Inc. (NYSE:PFE) by 5.7% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 247,805 shares of the biopharmaceutical company’s stock after purchasing an additional 13,350 shares during the period. Independent Advisor Alliance’s holdings in Pfizer were worth $6,574,000 at the end of the most recent quarter.

Several other institutional investors also recently bought and sold shares of PFE. Swedbank AB boosted its stake in shares of Pfizer by 0.7% in the third quarter. Swedbank AB now owns 5,745,831 shares of the biopharmaceutical company’s stock worth $166,284,000 after acquiring an additional 37,636 shares during the last quarter. United Bank boosted its stake in shares of Pfizer by 3.7% in the third quarter. United Bank now owns 35,599 shares of the biopharmaceutical company’s stock worth $1,030,000 after acquiring an additional 1,277 shares during the last quarter. Atria Investments Inc boosted its stake in shares of Pfizer by 1.1% in the third quarter. Atria Investments Inc now owns 300,430 shares of the biopharmaceutical company’s stock worth $8,694,000 after acquiring an additional 3,243 shares during the last quarter. Legacy Capital Wealth Partners LLC acquired a new stake in shares of Pfizer in the third quarter worth approximately $233,000. Finally, Baker Avenue Asset Management LP boosted its stake in shares of Pfizer by 9.1% in the third quarter. Baker Avenue Asset Management LP now owns 32,860 shares of the biopharmaceutical company’s stock worth $951,000 after acquiring an additional 2,738 shares during the last quarter. 68.36% of the stock is owned by institutional investors and hedge funds.

Insider Activity at Pfizer

In other news, Director Ronald E. Blaylock acquired 19,457 shares of the business’s stock in a transaction that occurred on Thursday, February 13th. The shares were purchased at an average price of $25.65 per share, for a total transaction of $499,072.05. Following the acquisition, the director now owns 27,707 shares of the company’s stock, valued at $710,684.55. This represents a 235.84 % increase in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Company insiders own 0.06% of the company’s stock.

Wall Street Analyst Weigh In

PFE has been the topic of a number of recent research reports. Bank of America reissued a “neutral” rating and set a $29.00 price objective on shares of Pfizer in a research note on Tuesday, December 10th. Truist Financial lowered their price objective on Pfizer from $36.00 to $32.00 and set a “buy” rating on the stock in a research note on Wednesday, December 18th. StockNews.com lowered Pfizer from a “strong-buy” rating to a “buy” rating in a research note on Wednesday, November 20th. UBS Group lowered their price objective on Pfizer from $31.00 to $29.00 and set a “neutral” rating on the stock in a research note on Wednesday, January 8th. Finally, Citigroup lowered their price objective on Pfizer from $30.00 to $29.00 and set a “neutral” rating on the stock in a research note on Tuesday, January 28th. One research analyst has rated the stock with a sell rating, eight have assigned a hold rating, six have given a buy rating and two have assigned a strong buy rating to the stock. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $31.92.

Pfizer Price Performance

PFE stock opened at $26.62 on Tuesday. The company has a current ratio of 1.00, a quick ratio of 0.73 and a debt-to-equity ratio of 0.63. The company has a market capitalization of $150.89 billion, a PE ratio of 18.88, a P/E/G ratio of 0.64 and a beta of 0.61. Pfizer Inc. has a 12-month low of $24.48 and a 12-month high of $31.54. The business’s fifty day moving average price is $26.30 and its 200 day moving average price is $27.21.

Pfizer (NYSE:PFE) last posted its quarterly earnings data on Tuesday, February 4th. The biopharmaceutical company reported $0.63 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.48 by $0.15. The firm had revenue of $17.76 billion for the quarter, compared to the consensus estimate of $17.26 billion. Pfizer had a return on equity of 19.47% and a net margin of 12.62%. The company’s quarterly revenue was up 24.7% compared to the same quarter last year. During the same quarter in the previous year, the business earned $0.10 EPS. On average, sell-side analysts anticipate that Pfizer Inc. will post 2.95 EPS for the current year.

Pfizer Increases Dividend

The company also recently disclosed a quarterly dividend, which was paid on Friday, March 7th. Investors of record on Friday, January 24th were issued a $0.43 dividend. This represents a $1.72 annualized dividend and a dividend yield of 6.46%. The ex-dividend date was Friday, January 24th. This is an increase from Pfizer’s previous quarterly dividend of $0.42. Pfizer’s payout ratio is currently 121.99%.

About Pfizer

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.